About us Contacts Drug interactions: 390 212
Drug search by name

Adempas and Verapamil Intravenous

Determining the interaction of Adempas and Verapamil Intravenous and the possibility of their joint administration.

Check result:
Adempas <> Verapamil Intravenous
Relevance: 02.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Verapamil may increase the blood levels of riociguat. You may be more likely to experience serious side effects such as low blood pressure and bleeding. The risk of other side effects such as dizziness, lightheadedness, fainting, headache, flushing, palpitation, nasal congestion, upset stomach, and constipation may also increase. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension. When riociguat was administered with ketoconazole, a potent CYP450 3A4 inhibitor that also inhibits P-gp and BCRP, riociguat peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.5- and 2.5-fold, respectively. The Cmax and AUC of the active metabolite, M1, which has 1/3 to 1/10 the pharmacologic activity of riociguat, were reduced by approximately 50% and 25%, respectively. Administration with the potent CYP450 3A4 inhibitor clarithromycin increased the AUC of riociguat by about 30%. The Cmax and AUC of M1 were not significantly altered (i.e.,

References
  • "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
Adempas

Generic Name: riociguat

Brand name: Adempas

Synonyms: n.a.

Verapamil Intravenous

Generic Name: verapamil

Brand name: Calan, Calan SR, Isoptin SR, Verelan, Isoptin, Isoptin IV, Covera-HS, Verelan PM

Synonyms: Verapamil (Intravenous)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction